BioCentury
ARTICLE | Company News

Daiichi Sankyo, Impax, Sanofi metabolic news

July 11, 2011 7:00 AM UTC

Impax, Daiichi and Sanofi's Genzyme Corp. subsidiary settled a pair of 2010 suits filed in the U.S. District Court for the District of Delaware related to Imapx's oral suspension and tablet generic versions of Daiichi's hypercholesterolemia drug Welchol colesevelam. Under the settlement, Impax can launch its tablet generic on March 2, 2015 or earlier under undisclosed terms. Impax can also launch its oral suspension generic under undisclosed terms. Impax believes it is the first to file an ANDA with a Paragraph IV certification for colesevelam tablets and expects three month of market exclusivity for its generic. ...